Otros idiomas Regeneron Pharmaceuticals, Inc.

Acciones

REGN

US75886F1075

Farmacéuticos

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 13/02/2026			Variación 5 días	Varia. 1 de enero.
803,17 ^USD	+2,49 %		+2,93 %	+4,06 %

13/02	REGENERON PHARMACEUTICALS, INC. : El HSBC continua con su recomendación de compra	ZM
11/02	Un directivo de Regeneron Pharmaceuticals vendió acciones por un valor de 1.585.058 dólares, según una reciente presentación ante la SEC	MT

Otros idiomas

11/02	Regeneron Pharmaceuticals Insider Sold Shares Worth $1,585,058, According to a Recent SEC Filing
11/02	Regeneron Announces Investor Conference Presentations
10/02	Regeneron Pipeline Progress Continues but Near-Term Visibility Remains Limited, RBC Says
10/02	Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
10/02	Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
10/02	Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
04/02	Regeneron Pharmaceuticals : Q4 2025 Earnings Conference Call Transcript
03/02	DZ Bank voit encore du potentiel sur Regeneron Pharmaceuticals
02/02	Regeneron Pharmaceuticals, Inc. Announces Upcoming Presentations from Its Ophthalmology Portfolio and Pipeline At the Virtual Angiogenesis Annual Meeting on February 7, 2026
02/02	Regeneron 2026 Outlook Balanced With Dupixent Growth, Sanofi Collaboration, RBC Says
02/02	EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
02/02	Sanofi's genetic disorder drug shows mixed results in late-stage trials
30/01	Regeneron bets added cholesterol benefit will help its obesity drug stand out
30/01	Regeneron beats expectations on Dupixent strength despite pressure on Eylea
30/01	Wall Street ouvre en baisse, Trump propose Kevin Warsh à la tête de la Fed
30/01	Sector Update: Health Care Stocks Fall Premarket Friday
30/01	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Geopolitical Tensions Loom While Investors Still Await Fed Rate Cut
30/01	Regeneron dépasse les attentes grâce à Dupixent, malgré les pressions sur Eylea
30/01	Regeneron Pharmaceuticals : Q4 2025 Earnings Conference Call
30/01	Regeneron Pharmaceuticals : Jan 2026 - REGN Corporate Presentation FINAL
30/01	Regeneron Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
30/01	Regeneron beats quarterly profit estimates on Dupixent strength
30/01	Tranche Update on Regeneron Pharmaceuticals, Inc.'s Equity Buyback Plan announced on February 4, 2025.
30/01	Regeneron Pharmaceuticals Q4 Adjusted Earnings Fall, Revenue Rises
30/01	Regeneron: Q4 Earnings Snapshot

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripciones Comunicados Publs. oficiales Otros idiomas Artículos de MarketScreener Estrategias MarketScreener Ideas de trading

Filtros

Acciones

Yancopoulos de Regeneron sobre la terapia génica para la pérdida de audición y los medicamentos para la pérdida de peso

13 de enero 2026 a las 22:08